|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. Effects of inhibiting MAP kinase signaling on specification of the SMCs.
Embryos were treated as above and whole-mount in situ hybridization was then
performed for Delta (A-F), CyIa (G-L), AA29 (M-R) and
23F (S-X). Control embryos on the left, U0126-treated embryos on the
right of the figure. U0126 treatment decreases the level of expression of
Delta at the early blastula (B5) but not at later stages. The mesodermal
expression of CyIa is suppressed at the mesenchyme blastula stage,
but unaffected at later stages. The oral ectoderm expression (arrow in G) is
unaffected. The expression of AA29 and 23F is reduced but
not suppressed by the treatment with U0126. Stages are the same as in
Fig. 4.
|
